Sector: N/A | Industry: N/A |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 520 Broad St NEWARK NJ 07120 |
Tel: | N/A |
Website: | https://rafaelholdings.com |
IR: | See website |
Key People | ||
Howard S. Jonas Executive Chairman of the Board | William Conkling President, Chief Executive Officer | David A. Polinsky Chief Financial Officer | John M. Goldberg Chief Medical Officer |
Business Overview |
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. The Company's segments include healthcare and real estate. The Company's investments include Cornerstone Pharmaceuticals, Inc., which is a cancer metabolism-based therapeutics company; LipoMedix Pharmaceuticals Ltd., which is a clinical-stage pharmaceutical company; Barer Institute Inc., which is a preclinical cancer metabolism research operation; Cyclo Therapeutics Inc., which is a clinical-stage biotechnology company dedicated to developing medicines for patients and families living with diseases through its therapeutic asset like Trappsol and Cyclo; Day Three Labs, Inc., which offers pharmaceutical-grade technology like Unlokt, and Rafael Medical Devices, LLC, which is an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries. Its real estate segment comprises of a portion of a commercial building in Israel. |
Financial Overview |
For the six months ended 31 January 2024, Rafael Holdings Inc revenues decreased 3% to $136K. Net income before extraordinary items totaled $2.4M vs. loss of $8.2M. Revenues reflect Rental - Third Party decrease of 5% to $82K. Net Income reflects Healthcare segment loss decrease of 40% to $5.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.36 to $0.10. |
Employees: | 13 as of Oct 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.28M as of Jan 31, 2024 |
EBITDA (TTM): | -$11.17M as of Jan 31, 2024 |
Net annual income (TTM): | $2.26M as of Jan 31, 2024 |
Free cash flow (TTM): | -$7.42M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 24,584,439 as of Mar 11, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |